12/4
09:09 am
insm
Insmed (NASDAQ:INSM) is now covered by analysts at Rothschild & Co Redburn. They set a "buy" rating and a $263.00 price target on the stock.
Low
Report
Insmed (NASDAQ:INSM) is now covered by analysts at Rothschild & Co Redburn. They set a "buy" rating and a $263.00 price target on the stock.
12/4
07:19 am
insm
Insmed (NASDAQ:INSM) was given a new $263.00 price target on by analysts at Redburn Partners.
Low
Report
Insmed (NASDAQ:INSM) was given a new $263.00 price target on by analysts at Redburn Partners.
12/4
07:00 am
insm
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12/2
01:01 pm
insm
Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
12/1
08:45 am
insm
Insmed (NASDAQ:INSM) was given a new $256.00 price target on by analysts at Mizuho.
Low
Report
Insmed (NASDAQ:INSM) was given a new $256.00 price target on by analysts at Mizuho.
11/20
11:04 am
insm
Insmed (NASDAQ:INSM) had its price target raised by analysts at TD Cowen from $223.00 to $231.00. They now have a "buy" rating on the stock.
Medium
Report
Insmed (NASDAQ:INSM) had its price target raised by analysts at TD Cowen from $223.00 to $231.00. They now have a "buy" rating on the stock.
11/20
09:05 am
insm
Insmed (NASDAQ:INSM) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Insmed (NASDAQ:INSM) had its "buy" rating reaffirmed by analysts at Cowen Inc.
11/18
09:58 pm
insm
Here's What Lifted Insmed Incorporated (INSM) in Q3 [Yahoo! Finance]
Low
Report
Here's What Lifted Insmed Incorporated (INSM) in Q3 [Yahoo! Finance]
11/18
11:21 am
insm
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union [Yahoo! Finance]
Low
Report
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union [Yahoo! Finance]
11/18
11:06 am
insm
European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
Low
Report
European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
11/18
11:00 am
insm
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
Low
Report
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
11/15
11:39 am
insm
A Fresh Look at Insmed (INSM) Valuation After Recent Share Price Surge [Yahoo! Finance]
Low
Report
A Fresh Look at Insmed (INSM) Valuation After Recent Share Price Surge [Yahoo! Finance]
11/13
07:00 am
insm
Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good
Low
Report
Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good
11/5
07:42 am
insm
Insmed To Present at November and December 2025 Investor Conferences [Yahoo! Finance]
Low
Report
Insmed To Present at November and December 2025 Investor Conferences [Yahoo! Finance]
11/5
07:00 am
insm
Insmed To Present at November and December 2025 Investor Conferences
Low
Report
Insmed To Present at November and December 2025 Investor Conferences
10/31
10:07 am
insm
Insmed (NASDAQ:INSM) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Insmed (NASDAQ:INSM) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
10/31
10:06 am
insm
Insmed (NASDAQ:INSM) was given a new $223.00 price target on by analysts at UBS Group AG.
Low
Report
Insmed (NASDAQ:INSM) was given a new $223.00 price target on by analysts at UBS Group AG.
10/31
10:05 am
insm
Insmed (NASDAQ:INSM) was given a new $215.00 price target on by analysts at Royal Bank Of Canada.
Low
Report
Insmed (NASDAQ:INSM) was given a new $215.00 price target on by analysts at Royal Bank Of Canada.
10/31
07:19 am
insm
Insmed (NASDAQ:INSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
Insmed (NASDAQ:INSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
10/30
08:03 pm
insm
Insmed (NASDAQ:INSM) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Medium
Report
Insmed (NASDAQ:INSM) had its "buy" rating reaffirmed by analysts at Cowen Inc.
10/30
07:00 am
insm
Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update
High
Report
Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update
10/29
10:59 am
insm
Insmed (NASDAQ:INSM) was given a new $196.00 price target on by analysts at Mizuho.
Low
Report
Insmed (NASDAQ:INSM) was given a new $196.00 price target on by analysts at Mizuho.
10/28
10:58 am
insm
Insmed (NASDAQ:INSM) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $192.00 price target on the stock.
Low
Report
Insmed (NASDAQ:INSM) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $192.00 price target on the stock.
10/27
01:45 pm
insm
Insmed (NASDAQ:INSM) had its price target raised by analysts at Bank of America Corporation from $142.00 to $187.00. They now have a "buy" rating on the stock.
Low
Report
Insmed (NASDAQ:INSM) had its price target raised by analysts at Bank of America Corporation from $142.00 to $187.00. They now have a "buy" rating on the stock.
10/23
04:05 pm
insm
Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
Low
Report
Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List